Brief: Aeon Biopharma Announces Clinical Update And Productive End-Of-Phase 2 Meeting With FDA On Abp-450 (Prabotulinumtoxina) For The Preventive Treatment Of Migraine
19/03/2024 22:17
March 19 (Reuters) - Aeon Biopharma Inc AEON.A :
* AEON BIOPHARMA ANNOUNCES CLINICAL UPDATE AND PRODUCTIVE
END-OF-PHASE 2 MEETING WITH FDA ON ABP-450 (PRABOTULINUMTOXINA)
FOR THE PREVENTIVE TREATMENT OF MIGRAINE
* AEON BIOPHARMA - FDA, CO ALIGN ON DESIGN & ENDPOINTS FOR
PROPOSED PIVOTAL PHASE 3 TRIALS FOR PREVENTIVE TREATMENT OF BOTH
EPISODIC & CHRONIC MIGRAINE
* AEON BIOPHARMA INC - INTERIM ANALYSIS FROM ONGOING PHASE 2
STUDY
IN CHRONIC MIGRAINE WILL NOW BE CONDUCTED AND DATA ARE EXPECTED
IN Q2 2024
* AEON BIOPHARMA INC - PREVIOUSLY STATED TIMELINE FOR
TOP-LINE
DATA ON COMPLETE COHORT REMAINS ON TRACK FOR Q3 2024
Source text for Eikon: ID:nGNX4gxVyL
Further company coverage: AEON.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition